Asvasiran binds N mRNA

Asvasiran (ALN-RSV01) is a naked siRNA targeting the RSV nucleocapsid protein. It was safe and efficient in two phase 2 trials, reducing bronchiolitis obliterans syndrome in lung transplant patients infected with RSV (Zamora et al., 2011; Gottlieb et al., 2015). In an earlier phase 2 study, asvasiran reduced the number of infected adult volunteers experimentally inoculated with RSV (DeVincenzo et al., 2010). Asvasiran is applied intranasally or as inhalation (reviewed in Loo et al., 2023).

Asvasiran（ALN-RSV01）是一种靶向呼吸道合胞病毒（RSV）核衣壳蛋白的裸露siRNA。该药物在两项2期临床试验中表现出安全性及高效性，能够降低感染RSV的肺移植患者支气管闭塞性综合征的发生率（Zamora等，2011；Gottlieb等，2015）。在一项早期的2期研究中，Asvasiran降低了实验性接种RSV的成年志愿者感染人数（DeVincenzo等，2010）。Asvasiran可通过鼻腔给药或吸入给药（见Loo等，2023年综述）。